U. S. Food and Drug Administration's panel of advisers gave a statement that they no longer support the use and marketing of `calcitonin salmon' for the treatment of osteoporosis in post-menopausal women. The panel voted the drug out of its recommendations that it potentially increases the risk of cancer more than the treatment of osteoporosis by bone-thinning.
After the death of a 14-year-old patient in a clinical trial because of Amgen's Sensipar, the Food and Drug Administration has given orders to restrict the use of Sensipar in pediatric patients' clinical studies. However, the agency has not revealed about the surety of the drug having killed the boy.
Lombard Medical Technologies had developed a device dubbed Aorfix stent. It has been revealed that the US Food and Drug Administration has given green signal to the company for the new product.
The aim of the firm is to increase its operations at its Scottish manufacturing plant. And probably, the approval means the company's first step on the way to enhancing operations.